Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 0.53 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333431 | 1.00 | HTR4 (0.53) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL2331750 | 1.00 | HTR4 (0.53) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL5316450 | 0.99 | HTR4 (0.53) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL5332277 | 0.89 | HTR4 (0.47) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5364948 | 0.88 | HTR4 (0.48) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5364954 | 0.88 | HTR4 (0.48) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL17978222 | 0.88 | HTR4 (0.50) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL18019924 | 0.88 | HTR4 (0.50) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL17978212 | 0.88 | HTR4 (0.50) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL2329530 | 0.88 | HTR4 (0.51) | HTR4HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RQUALIA PHAMRA INC. (JP) | 2012-12-20 | — | — | US | claimed |
| EP-2533780-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RaQualia Pharma Inc (JP) | 2012-12-19 | — | — | EP | claimed |
| CN-102753172-A | 5-HT4 receptor agonists for the treatment of dementia | RAQUALIA PHARMA INC | 2012-10-24 | — | — | CN | claimed |
| WO-2011099305-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RAQUALIA PHARMA INC. (JP) | 2011-08-18 | — | — | WO | claimed |
| EP-2533780-B1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | ASKAT INC (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-8980922-B2 | 5-HT4 receptor agonists for the treatment of dementia | RAQUALIA PHARMA INC. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RQUALIA PHAMRA INC. (JP) | 2012-12-20 | — | — | US | disclosed |
| EP-2533780-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RaQualia Pharma Inc (JP) | 2012-12-19 | — | — | EP | disclosed |
| CN-102753172-A | 5-HT4 receptor agonists for the treatment of dementia | RAQUALIA PHARMA INC | 2012-10-24 | — | — | CN | disclosed |
| WO-2011099305-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RAQUALIA PHARMA INC. (JP) | 2011-08-18 | — | — | WO | disclosed |
| WO-2007068739-A1 | 4-AMINO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | HTR4, HTR5A, HTR1A | HTR4 1/4885HTR3A 14/4885HTR3E 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.